SCHEMBL4116154

SCHEMBL4116154

O=C(O)c1cc(NCCc2ccc(C(F)(F)F)cc2)ccc1O.[KH]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.52
PPARA Q07869 1/20 0.52
STING1 Q86WV6 1/20 0.52
FFAR1 O14842 1/20 0.49
NOX4 Q9NPH5 2/20 0.47
LCK P06239 2/20 0.47
RGS12 O14924 1/20 0.47
ALDH1A1 P00352 1/20 0.47
EGFR P00533 1/20 0.47
MAPT P10636 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CNR1 P21554 1/20 0.46
MCL1 Q07820 2/20 0.46
BCL2A1 Q16548 1/20 0.46
P2RX1 P51575 1/20 0.45
P2RX4 Q99571 1/20 0.45
P2RX7 Q99572 1/20 0.45
TMPRSS4 Q9NRS4 1/20 0.45
RORC P51449 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608498 0.99 KDM4C (0.53) KDM4CPPARASTING1FFAR1NOX4
Sulfuric Acid SCHEMBL1170031 0.94 PPARA (0.49) KDM4CPPARASTING1FFAR1NOX4
SCHEMBL609853 0.91 KDM4C (0.51) KDM4CPPARASTING1FFAR1NOX4
SCHEMBL608886 0.88 KDM4C (0.50) KDM4CPPARASTING1NOX4LCK
SCHEMBL29390264 0.87 KDM4C (0.69) KDM4CPPARASTING1FFAR1NOX4
SCHEMBL607106 0.87 KDM4C (0.69) KDM4CPPARASTING1FFAR1NOX4
Potassium Ion SCHEMBL4116152 0.86 RORC (0.47) KDM4CPPARASTING1FFAR1CNR1
SCHEMBL608043 0.85 CNR1 (0.52) KDM4CPPARASTING1FFAR1NOX4
SCHEMBL29390970 0.85 CNR1 (0.52) KDM4CPPARASTING1FFAR1NOX4
SCHEMBL1169878 0.85 EGFR (0.52) FFAR1NOX4EGFRMAPTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004164-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2018-08-08 EP disclosed
US-8598383-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-12-03 US disclosed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 US disclosed
CN-103211824-A Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO LTD 2013-07-24 CN disclosed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 US disclosed
CN-101426484-B Application of pharmaceutical composition in preparation of medicines for treating or preventing degenerative and inflammatory diseases NEUROTECH CO LTD 2013-05-22 CN disclosed
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GWAG BYOUNG-JOO (KR) 2012-08-16 US disclosed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 US disclosed
US-20090240079-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2009-09-24 US disclosed
CN-101426484-A Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH CO LTD (KR) 2009-05-06 CN disclosed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 EP disclosed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B KDM4C 4051/4885PPARA 223/4885STING1 3665/4885
US-20090240079-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B KDM4C 4051/4885PPARA 223/4885STING1 3665/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B KDM4C 4051/4885PPARA 223/4885STING1 3665/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B KDM4C 4051/4885PPARA 223/4885STING1 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.